MeiraGTx reports positive Phase 2 data for AAV-GAD in Parkinson's; 18-point UPDRS improvement in high-dose group

MeiraGTx Holdings plc

AAV-GAD met primary safety endpoint; no SAEs related to treatment in 14-patient bridging study.
High-dose group showed 18-point average improvement in UPDRS Part 3 off-medication (p=0.03); sham and low-dose showed no significant change.
PDQ-39 quality-of-life score improved by 8 points (p=0.02) in high-dose and 6 points (p=0.04) in low-dose groups.
100% of high-dose participants reported PDQ-39 improvement vs 60% low-dose and 25% sham.
Company plans to advance AAV-GAD into Phase 3 trial globally; total of 58 patients treated across program with no related SAEs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.